Eroglu E, Pamuk A, Ozer S, Onerci T
Turk Arch Otorhinolaryngol. 2024; 62(2):42-47.
PMID: 39463065
PMC: 11572336.
DOI: 10.4274/tao.2024.2024-1-2.
Cao X, Huang H, Liang C, Lin Z, Zhou J, Chen X
Nat Commun. 2024; 15(1):949.
PMID: 38297016
PMC: 10831082.
DOI: 10.1038/s41467-024-45276-1.
Li G, Yang S, Wang S, Jiang R, Xu X
Diagnostics (Basel). 2023; 13(15).
PMID: 37568893
PMC: 10417831.
DOI: 10.3390/diagnostics13152530.
Yang X, Ren H, Li M, Zhu Y, Zhang W, Fu J
Ann Med. 2023; 55(1):2200257.
PMID: 37074291
PMC: 10120450.
DOI: 10.1080/07853890.2023.2200257.
Tanjararak K, Tangbumrungtham N, Plumworasawat S, Roongpuvapaht B
Indian J Otolaryngol Head Neck Surg. 2022; 74(Suppl 2):911-917.
PMID: 36452824
PMC: 9702495.
DOI: 10.1007/s12070-020-02000-x.
Recurrent Nasopharyngeal Cancer: Critical Review of Local Treatment Options Including Recommendations during the COVID-19 Pandemic.
Svajdova M, Sicak M, Dubinsky P, Slavik M, Slampa P, Kazda T
Cancers (Basel). 2020; 12(12).
PMID: 33255751
PMC: 7760235.
DOI: 10.3390/cancers12123510.
Modified Maxillary-Swing Approach for Resection of Primary Malignancies in the Pterygopalatine Fossa.
Xie L, Huang W, Wang J, Zhou Y, Chen J, Chen X
Front Oncol. 2020; 10:530381.
PMID: 33240804
PMC: 7682189.
DOI: 10.3389/fonc.2020.530381.
Intensity-modulated carbon-ion radiation therapy versus intensity-modulated photon-based radiation therapy in locally recurrent nasopharyngeal carcinoma: a dosimetric comparison.
Wang L, Hu J, Liu X, Wang W, Kong L, Lu J
Cancer Manag Res. 2019; 11:7767-7777.
PMID: 31496819
PMC: 6701671.
DOI: 10.2147/CMAR.S205421.
Current Treatment Landscape of Nasopharyngeal Carcinoma and Potential Trials Evaluating the Value of Immunotherapy.
Le Q, Colevas A, OSullivan B, Lee A, Lee N, Ma B
J Natl Cancer Inst. 2019; 111(7):655-663.
PMID: 30912808
PMC: 7962891.
DOI: 10.1093/jnci/djz044.
Management of recurrent nasopharyngeal carcinoma: current perspectives.
Perri F, Della Vittoria Scarpati G, Caponigro F, Ionna F, Longo F, Buonopane S
Onco Targets Ther. 2019; 12:1583-1591.
PMID: 30881013
PMC: 6396653.
DOI: 10.2147/OTT.S188148.
[Robotic Surgery - Who is The Boss?].
Schuler P
Laryngorhinootologie. 2018; 97(S 01):S231-S278.
PMID: 29905359
PMC: 6541110.
DOI: 10.1055/s-0043-121791.
Salvage surgery for nasopharyngeal cancer.
Tsang R, Wei W
World J Otorhinolaryngol Head Neck Surg. 2017; 1(1):34-43.
PMID: 29204538
PMC: 5698510.
DOI: 10.1016/j.wjorl.2015.09.006.
Metronomic oral cyclosphosphamide as third-line systemic treatment or beyond in patients with inoperable locoregionally advanced recurrent or metastatic nasopharyngeal carcinoma.
Lee V, Kwong D, Lam K, Lai Y, Li Y, Tong C
Medicine (Baltimore). 2017; 96(15):e6518.
PMID: 28403082
PMC: 5403079.
DOI: 10.1097/MD.0000000000006518.
Phase I/II trial evaluating concurrent carbon-ion radiotherapy plus chemotherapy for salvage treatment of locally recurrent nasopharyngeal carcinoma.
Kong L, Gao J, Hu J, Hu W, Guan X, Lu R
Chin J Cancer. 2016; 35(1):101.
PMID: 28007028
PMC: 5178073.
DOI: 10.1186/s40880-016-0164-5.
Hyperfractionation compared to standard fractionation in intensity-modulated radiation therapy for patients with locally advanced recurrent nasopharyngeal carcinoma.
Lee V, Kwong D, Leung T, Ng S, Lam K, Tong C
Eur Arch Otorhinolaryngol. 2016; 274(2):1067-1078.
PMID: 27738820
DOI: 10.1007/s00405-016-4339-0.
Phase I/II Trial Evaluating Carbon Ion Radiotherapy for Salvaging Treatment of Locally Recurrent Nasopharyngeal Carcinoma.
Kong L, Hu J, Guan X, Gao J, Lu R, Lu J
J Cancer. 2016; 7(7):774-83.
PMID: 27162535
PMC: 4860793.
DOI: 10.7150/jca.14399.
Salvage surgery for neck residue or recurrence of nasopharyngeal carcinoma after primary radiotherapy: options of surgical methods and regions.
Wang S, Lou J, Chen J, Zhang S, Guo L
World J Surg Oncol. 2016; 14:89.
PMID: 27012522
PMC: 4807573.
DOI: 10.1186/s12957-016-0822-8.
Pretreatment (18)F-FDG uptake heterogeneity can predict survival in patients with locally advanced nasopharyngeal carcinoma--a retrospective study.
Yang Z, Shi Q, Zhang Y, Pan H, Yao Z, Hu S
Radiat Oncol. 2015; 10:4.
PMID: 25566697
PMC: 4311496.
DOI: 10.1186/s13014-014-0268-5.
Therapeutic implications of Epstein-Barr virus infection for the treatment of nasopharyngeal carcinoma.
Hutajulu S, Kurnianda J, Tan I, Middeldorp J
Ther Clin Risk Manag. 2014; 10:721-36.
PMID: 25228810
PMC: 4161530.
DOI: 10.2147/TCRM.S47434.
Differential expression of long noncoding RNA in primary and recurrent nasopharyngeal carcinoma.
Gao W, Yu-Wai Chan J, Wong T
Biomed Res Int. 2014; 2014:404567.
PMID: 24822202
PMC: 4009106.
DOI: 10.1155/2014/404567.